CureVac N.V (CVAC): Price and Financial Metrics

CureVac N.V (CVAC): $3.67

0.05 (-1.34%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

F

Add CVAC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#251 of 340

in industry

CVAC Price/Volume Stats

Current price $3.67 52-week high $10.14
Prev. close $3.72 52-week low $2.21
Day low $3.60 Volume 671,900
Day high $3.78 Avg. volume 1,052,402
50-day MA $3.58 Dividend yield N/A
200-day MA $4.01 Market Cap 821.64M

CVAC Stock Price Chart Interactive Chart >


CureVac N.V (CVAC) Company Bio


CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.(Source:Wikipedia)


CVAC Latest News Stream


Event/Time News Detail
Loading, please wait...

CVAC Latest Social Stream


Loading social stream, please wait...

View Full CVAC Social Stream

Latest CVAC News From Around the Web

Below are the latest news stories about CUREVAC NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.

These Analysts Just Made A Huge Downgrade To Their CureVac N.V. (NASDAQ:CVAC) EPS Forecasts

One thing we could say about the analysts on CureVac N.V. ( NASDAQ:CVAC ) - they aren't optimistic, having just made a...

Yahoo | December 22, 2023

Rebel's Edge - December 19: $RUN, $AFRM, $CVAC, and College Football Recruits

Jon and Pete Najarian join forces to discuss and debate their favorite topics, including the hottest stock-specific news and sports!

Yahoo | December 19, 2023

Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?

A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights utilized in Comirnaty, BioNTech, and Pfizer Inc's (NYSE: PFE) mRNA COVID-19 vaccine. The ruling represents the first decision on validity in ongoing patent litigation between CureVac and BioNTech in Germany, involving eight CureVac intellectual property rights. Proc

Yahoo | December 19, 2023

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE Decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering strong foundational ...

Yahoo | December 19, 2023

UPDATE 2-German court quashes CureVac patent after challenge by BioNTech

A German court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, in a blow to CureVac's claims for a share in billions of euros in COVID-19 vaccine revenues. CureVac's Nasdaq-listed shares plunged 35% to a record low after the verdict.

Yahoo | December 19, 2023

Read More 'CVAC' Stories Here

CVAC Price Returns

1-mo 12.58%
3-mo 50.41%
6-mo -3.42%
1-year -60.92%
3-year -93.16%
5-year N/A
YTD -12.83%
2023 -30.18%
2022 -82.42%
2021 -57.68%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!